3D hESC exosomes enriched with miR-6766-3p ameliorates liver fibrosis by attenuating activated stellate cells through targeting the TGFβRII-SMADS pathway
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background: Exosomes secreted from stem cells exerted salutary effects on the fibrotic liver. Herein, the roles of exosomes derived from human embryonic stem cell (hESC) in anti-fibrosis were extensively investigated. Compared with two-dimensional (2D) culture, the clinical and biological relevance of three-dimensional (3D) cell spheroids were greater because of their higher regeneration potential since they behave more like cells in vivo. In our study, exosomes derived from 3D human embryonic stem cells (hESC) spheroids and the monolayer (2D) hESCs were collected and compared the therapeutic potential for fibrotic liver in vitro and in vivo. Results: In vitro, PKH26 labeled-hESC-Exosomes were shown to be internalized and integrated into TGFβ-activated-LX2 cells, and reduced the expression of profibrogenic markers, thereby regulating cellular phenotypes. TPEF imaging indicated that PKH26-labeled-3D-hESC-Exsomes possessed an enhanced capacity to accumulate in the livers and exhibited more dramatic therapeutic potential in the injured livers of fibrosis mouse model. 3D-hESC-Exosomes decreased profibrogenic markers and liver injury markers, and improved the level of liver functioning proteins, eventually restoring liver function of fibrosis mice. miRNA array revealed a significant enrichment of miR-6766-3p in 3D-hESC-Exosomes, moreover, bioinformatics and dual luciferase reporter assay identified and confirmed the TGFβRII gene as the target of miR-6766-3p. Furthermore, the delivery of miR-6766-3p into activated-LX2 cells decreased cell proliferation, chemotaxis and profibrotic effects, and further investigation demonstrated that the expression of target gene TGFβRII and its downstream SMADs proteins, especially phosphorylated protein p-SMAD2/3 was also notably down-regulated by miR-6766-3p. These findings unveiled that miR-6766-3p in 3D-hESC-Exosomes inactivated SMADs signaling by inhibiting TGFβRII expression, consequently attenuating stellate cell activation and suppressing liver fibrosis. Conclusions: Our results showed that miR-6766-3p in the 3D-hESC-Exosomes inactivates smads signaling by restraining TGFβRII expression, attenuated LX2 cell activation and suppressed liver fibrosis, suggesting that 3D-hESC-Exosome enriched-miR-6766-3p is a novel anti-fibrotic therapeutics for treating chronic liver disease. These results also proposed a significant strategy that 3D-Exo could be used as natural nanoparticles to rescue liver injury via delivering antifibrotic miR-6766-3p. Graphical Abstract:
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hippo pathway effector YAP controls mouse hepatic stellate cell activation
Mannaerts, I., Leite, S. B., Verhulst, S., Claerhout, S., Eysackers, N., Thoen, L. F. R., Hoorens, A., Reynaert, H., Halder, G., & van Grunsven, L. A. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.011 · Cited by 410
Mesenchymal stem cell therapy for liver fibrosis
Eom, Y. W., Shim, K. Y., & Baik, S. K. (2015) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.30.5.580 · Cited by 226 · cited 1×
“As a result, liver repair with exogenous stem cells provides an alternative for liver organ or cell transplantation [10].”
Background
Cited by
Clinical applications of stem cell-derived exosomes
Tan, F., Li, X., Wang, Z., Li, J., Shahzad, K., & Zheng, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01704-0 · Cited by 708
Self-citationPlant-Derived Exosome-Like Nanovesicles: Current Progress and Prospects
Mu, N., Li, J., Zeng, L., You, J., Li, R., Qin, A., Liu, X., Yan, F., & Zhou, Z. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s420748 · Cited by 265
Self-citationLiver fibrosis resolution: from molecular mechanisms to therapeutic opportunities
Pei, Q., Yi, Q., & Tang, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119671 · Cited by 121
Mesenchymal Stem Cell–Derived Exosomes in Various Chronic Liver Diseases: Hype or Hope?
Zhu, L., Wang, Q., Guo, M., Fang, H., Li, T., Zhu, Y., Jiang, H., Xiao, P., & Hu, M. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s439974 · Cited by 21
Extracellular vesicles: emerging therapeutic agents for liver fibrosis
Chiabotto, G., Semnani, A., Ceccotti, E., & Bruno, S. (2025) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2025.08 · Cited by 13
Metadata
- Authors
- Wang, N., Li, X., Zhong, Z., Qiu, Y., Liu, S., Wu, H., Tang, X., Chen, C., Fu, Y., Chen, Q., Guo, T., Li, J., Zhang, S., Zern, M. A., Ma, K., Wang, B., Ou, Y., Gu, W., Cao, J., Chen, H., & Duan, Y.
- Venue
- Journal of Nanobiotechnology
- Published
- 2021-12
- Volume
- 19
- Issue
- 1
- Pages
- 437-437
- ISSN
- 1477-3155 (ISSN-L)
- OpenAlex
- W4226324006
- Cited by
- 73
- References
- 2
- FWCI
- 3.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 3D hESC exosomes enriched with miR-6766-3p ameliorates liver fibrosis by attenuating activated stellate cells through targeting the TGFβRII-SMADS pathway. https://app.cochat.ai/papers/10.1186/s12951-021-01138-2
- The paper
- Wang, N., Li, X., Zhong, Z., Qiu, Y., Liu, S., Wu, H., Tang, X., Chen, C., Fu, Y., Chen, Q., Guo, T., Li, J., Zhang, S., Zern, M. A., Ma, K., Wang, B., Ou, Y., Gu, W., Cao, J., . . . Duan, Y. (2021). 3D hESC exosomes enriched with miR-6766-3p ameliorates liver fibrosis by attenuating activated stellate cells through targeting the TGFβRII-SMADS pathway. Journal of Nanobiotechnology. https://doi.org/10.1186/s12951-021-01138-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.